Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Roche’s oral PI3K inhibitor Itovebi (inavolisib) has been approved by the European Commission (EC) as part of a combination ...

Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4 Itovebi is the first PI3K-targeted therapy to ...

Menopause can feel like one big balancing act. Between managing your hormone levels and symptoms like hot flashes, night ...

YourChoice Therapeutics, Inc., pioneering hormone-free family planning products, today announced that Communications Medicine ...

I Orion’s collaboration partner Bayer announced today that the European Commission has granted marketing authorization in the European Union ...

The breakthrough could spare thousands of patients unnecessary therapy while allowing others to receive more intensive care ...

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.

Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.